Ebolavirus: a brief review of novel therapeutic targets - 2012

[Emily]

PDF format.

Ebolavirus: a brief review of novel therapeutic targets
http://www.futuremedicine.com/doi/pdf/10.2217/fmb.11.110

 

[JohnnyD]

Re: Ebolavirus: a brief review of novel therapeutic targets

Re: Ebolavirus: a brief review of novel therapeutic targets

From the article, which is from 2012:

?...given the questionable
financial incentive of developing
EBOV-specific antivirals or vaccines,
future cures for EBOV might stem from
broad-efficacy antivirals.?

Hemispherx Biopharma now has both of their broad spectrum antivirals in the top BSL4 labs in the country and also with the Swiss Dept of Defense. I believe this company may be a player.
------
Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators
Hemispherx's Two Experimental Therapeutics May Provide Benefit Despite Recently Discovered Ebola Viral Mutations

http://finance.yahoo.com/news/hemispherx-biopharma-expands-research-potential-123000003.html

 

[AlaskaDenise]

Re: Ebolavirus: a brief review of novel therapeutic targets - 2012

Here are some studies discussing the effectiveness of 2 anti-cancer drugs against EBOV:

Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase

.....The drug nilotinib or siRNAs directed against c-Abl1 also reduced productive replication of the Zaire strain of Ebola virus in cultured Vero cells by up to four orders of magnitude......

.....These findings suggest that drugs such as nilotinib that inhibit c-Abl1 and are already in clinical use as anticancer therapeutics may be useful for reducing the severity of Ebola virus infection.

-------------------------

FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection

.....This anti-EBOV activity occurred even in the absence of detectable estrogen receptor expression, and both SERMs inhibited virus entry after internalization, suggesting that clomiphene and toremifene are not working through classical pathways associated with the estrogen receptor. Instead, the response appeared to be an off-target effect where the compounds interfere with a step late in viral entry and likely affect the triggering of fusion.....

--------------------------------------------------

Another SERM is tamoxifen - a common anti-cancer drug for breast cancer prevention and recurrence.

.